|vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for ...|
Azeliragon's novel mechanism allows for targeting a receptor we believe is involved in multiple pathologic processes leading to the development and progression of Alzheimer's disease." The STEADFAST Study will investigate the efficacy of azeliragon ...
News-Medical.net - Tue, 19 May 2015 09:52
|Public Release: 18-May-2015 What hundreds of biomolecules tell us about our ...|
Neurodegenerative processes, such as those occurring in Parkinson's disease, are characterized by pathological alterations of the brain cells: these cells lose their structure and function, a process that is accompanied by changes in their metabolism.
EurekAlert (press release) - Mon, 18 May 2015 07:03
|vTv Therapeutics begins phase 3 trial evaluating azeliragon to treat patients ...|
vTv Therapeutics LLC (vTv),a clinical-stage biopharmaceutical company, has initiated enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's phase 3 placebo ...
pharmabiz.com - Thu, 21 May 2015 00:18
|CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal ...|
154, Anshan Road, Heping District, Tianjin 300052, ChinaE-mail: email@example.com; Dr W Zhang, Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 85, Houston 77030, TX, USA. E-mail: wzhang ...
Nature.com - Mon, 11 May 2015 03:52
|Proctor Medal lecturer focuses on retinal vascular growth research|
Vessel assembly can be a complex process that is regulated by a number of growth factor and cell-to-cell interactions, D'Amore said. Pathologic processes summarize normal processes, “which is something many years ago we did not have the knowledge of, ...
Healio - Wed, 06 May 2015 07:33
|Study Shows Role of Disease-Fighting Cells in HIV-Related Neurological Damage|
"We now know what cells bring the virus to the brain and what cells contribute to neurological damage in the brain, as well as the timing of the entry of these cells and when the pathologic virus enters. These are two big questions researchers have had.".
Scicasts (press release) (blog) - Tue, 12 May 2015 11:11
|Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ...|
These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. COMETRIQ® (cabozantinib) is currently ...
Yahoo Finance UK - Thu, 30 Apr 2015 13:15
|vTv Therapeutics begins Phase III trial of azeliragon to treat mild Alzheimer ...|
"Azeliragon's novel mechanism allows for targeting a receptor we believe is involved in multiple pathologic processes leading to the development and progression of Alzheimer's disease." The Steadfast trial is designed to evaluate the efficacy of ...
Pharmaceutical Business Review - Wed, 20 May 2015 05:22